DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.

doi:10.1093/jac/dkae194

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.

The Journal of antimicrobial chemotherapy - 1 Aug 2024

Soulie Cathia, Balde Aliou, Fofana Djeneba, Charpentier Charlotte, Bonnafous Pascale, Sourice Justine, De Monte Anne, Avettand-Fenoel Véronique, Le Guillou-Guillemette Hélène, Bocket Laurence, Raymond Stéphanie, Marque Juillet Stéphanie, Trabaud Mary-Anne, Montes Brigitte, Maillard Anne, Hartard Cédric, Alessandri-Gradt Elodie, Brochot Etienne, Signori-Schmuck Anne, Assoumou Lambert, Marcelin Anne-Geneviève

Abstract excerpt

BACKGROUND: Doravirine is the latest NNRTI to be approved for the treatment of HIV-1 and has a different resistance profile from first-generation NNRTIs. Our aim was to investigate the virological efficacy of antiretroviral treatment including doravirine in people living with HIV-1 (PLWHIV), the factors associated with virological failure (VF) and those associated with the emergence of reverse transcriptase (RT)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiretroviral Therapy, Highly Active

Share to Drug Resistance, Viral

Share to France

Share to HIV Reverse Transcriptase

Share to Pyridones

Share to Triazoles

Share to Viral Load

Source

Open in PubMed

Identifiers

PMID: 38884154
DOI: 10.1093/jac/dkae194

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.PMID 38884154Read ↗

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.Semantic proximity Read ↗

Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.Semantic proximity Read ↗

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.Semantic proximity Read ↗

Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.Semantic proximity Read ↗

Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV.Semantic proximity Read ↗

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to DoravirineSemantic proximity Read ↗

No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimensSemantic proximity Read ↗

Potential Role of Doravirine for the Treatment of Patients with Transmitted Drug ResistanceSemantic proximity Read ↗

Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.Semantic proximity Read ↗

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.Semantic proximity Read ↗

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine.Semantic proximity Read ↗

Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.